RSS

aducanumab

In a surprise announcement, pharma company Biogen has revealed it is set to pursue FDA approval for its Alzheimer’s drug aducanumab, which was previously discontinued in March earlier this year. Read more

News

An option exercise to further reduce the royalty rates payable on potential future sales of aducanumab — a Phase III investigational treatment for early Alzheimer’s disease — has been announced by Biogen and Neurimmune. Read more

News